Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

D. Behl; Luis F. Porrata; S. N. Markovic; L. Letendre; R. K. Pruthi; C. C. Hook; A. Tefferi; M. A. Elliot; S. H. Kaufmann; R. A. Mesa; Mark R. Litzow

doi:10.1038/sj.leu.2404032

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

D. Behl, Luis F. Porrata, S. N. Markovic, L. Letendre, R. K. Pruthi, C. C. Hook, A. Tefferi, M. A. Elliot, S. H. Kaufmann, R. A. Mesa, Mark R. Litzow

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Abstract

Absolute lymphocyte count (ALC) recovery postautologous stem cell transplantation is an independent predictor for survival in acute myelogenous leukemia (AML). The role of ALC recovery after induction chemotherapy (IC) in AML is unknown. We hypothesize that ALC recovery after IC has a direct impact on survival. We have now evaluated the impact of ALC recovery after IC on overall survival (OS) and leukemia-free survival (LFS) in 103 consecutive, newly diagnosed AML patients treated with standard IC and consolidation chemotherapy (CC) from 1998 to 2002. ALC recovery was studied at days 15 (ALC-15), 21 (ALC-21), 28 (ALC-28) after IC and before the first CC (ALC-CC). Superior OS and LFS at each time point were observed with an ALC-15, ALC-21, ALC-28, and ALC-CC ≥500 cells/μl. Patients with an ALC ≥500 cells/μl at all time points vs those who did not have superior OS and LFS (not reached vs 13 months, P<0.0001; and not reached vs 11 months, P<0.0001, respectively). Multivariate analysis demonstrated ALC ≥500cells/μl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML.

Original language	English (US)
Pages (from-to)	29-34
Number of pages	6
Journal	Leukemia
Volume	20
Issue number	1
DOIs	https://doi.org/10.1038/sj.leu.2404032
State	Published - Jan 2006

Keywords

Absolute lymphocyte count
Acute myelogenous leukemia
And induction chemotherapy

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/sj.leu.2404032

Cite this

@article{b62c7e16d9c241ddb3ddd13124b8de2f,

title = "Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia",

abstract = "Absolute lymphocyte count (ALC) recovery postautologous stem cell transplantation is an independent predictor for survival in acute myelogenous leukemia (AML). The role of ALC recovery after induction chemotherapy (IC) in AML is unknown. We hypothesize that ALC recovery after IC has a direct impact on survival. We have now evaluated the impact of ALC recovery after IC on overall survival (OS) and leukemia-free survival (LFS) in 103 consecutive, newly diagnosed AML patients treated with standard IC and consolidation chemotherapy (CC) from 1998 to 2002. ALC recovery was studied at days 15 (ALC-15), 21 (ALC-21), 28 (ALC-28) after IC and before the first CC (ALC-CC). Superior OS and LFS at each time point were observed with an ALC-15, ALC-21, ALC-28, and ALC-CC ≥500 cells/μl. Patients with an ALC ≥500 cells/μl at all time points vs those who did not have superior OS and LFS (not reached vs 13 months, P<0.0001; and not reached vs 11 months, P<0.0001, respectively). Multivariate analysis demonstrated ALC ≥500cells/μl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML.",

keywords = "Absolute lymphocyte count, Acute myelogenous leukemia, And induction chemotherapy",

author = "D. Behl and Porrata, {Luis F.} and Markovic, {S. N.} and L. Letendre and Pruthi, {R. K.} and Hook, {C. C.} and A. Tefferi and Elliot, {M. A.} and Kaufmann, {S. H.} and Mesa, {R. A.} and Litzow, {Mark R.}",

year = "2006",

month = jan,

doi = "10.1038/sj.leu.2404032",

language = "English (US)",

volume = "20",

pages = "29--34",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

AU - Behl, D.

AU - Porrata, Luis F.

AU - Markovic, S. N.

AU - Letendre, L.

AU - Pruthi, R. K.

AU - Hook, C. C.

AU - Tefferi, A.

AU - Elliot, M. A.

AU - Kaufmann, S. H.

AU - Mesa, R. A.

AU - Litzow, Mark R.

PY - 2006/1

Y1 - 2006/1

N2 - Absolute lymphocyte count (ALC) recovery postautologous stem cell transplantation is an independent predictor for survival in acute myelogenous leukemia (AML). The role of ALC recovery after induction chemotherapy (IC) in AML is unknown. We hypothesize that ALC recovery after IC has a direct impact on survival. We have now evaluated the impact of ALC recovery after IC on overall survival (OS) and leukemia-free survival (LFS) in 103 consecutive, newly diagnosed AML patients treated with standard IC and consolidation chemotherapy (CC) from 1998 to 2002. ALC recovery was studied at days 15 (ALC-15), 21 (ALC-21), 28 (ALC-28) after IC and before the first CC (ALC-CC). Superior OS and LFS at each time point were observed with an ALC-15, ALC-21, ALC-28, and ALC-CC ≥500 cells/μl. Patients with an ALC ≥500 cells/μl at all time points vs those who did not have superior OS and LFS (not reached vs 13 months, P<0.0001; and not reached vs 11 months, P<0.0001, respectively). Multivariate analysis demonstrated ALC ≥500cells/μl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML.

AB - Absolute lymphocyte count (ALC) recovery postautologous stem cell transplantation is an independent predictor for survival in acute myelogenous leukemia (AML). The role of ALC recovery after induction chemotherapy (IC) in AML is unknown. We hypothesize that ALC recovery after IC has a direct impact on survival. We have now evaluated the impact of ALC recovery after IC on overall survival (OS) and leukemia-free survival (LFS) in 103 consecutive, newly diagnosed AML patients treated with standard IC and consolidation chemotherapy (CC) from 1998 to 2002. ALC recovery was studied at days 15 (ALC-15), 21 (ALC-21), 28 (ALC-28) after IC and before the first CC (ALC-CC). Superior OS and LFS at each time point were observed with an ALC-15, ALC-21, ALC-28, and ALC-CC ≥500 cells/μl. Patients with an ALC ≥500 cells/μl at all time points vs those who did not have superior OS and LFS (not reached vs 13 months, P<0.0001; and not reached vs 11 months, P<0.0001, respectively). Multivariate analysis demonstrated ALC ≥500cells/μl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML.

KW - Absolute lymphocyte count

KW - Acute myelogenous leukemia

KW - And induction chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33644977449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644977449&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404032

DO - 10.1038/sj.leu.2404032

M3 - Article

C2 - 16281063

AN - SCOPUS:33644977449

SN - 0887-6924

VL - 20

SP - 29

EP - 34

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this